The role of MT1-MMP in the progression and metastasis of osteosarcoma

被引：1

作者：

Spencer, Hannah L. M. ^{[1
]}

Shnyder, Steven D. ^{[1
]}

Loadman, Paul M. ^{[1
]}

Falconer, Robert A. ^{[1
]}

机构：

[1] Univ Bradford, Inst Canc Therapeut, Fac Life Sci, Bradford BD7 1DP, W Yorkshire, England

来源：

JOURNAL OF CANCER METASTASIS AND TREATMENT | 2022年 / 8卷

关键词：

Matrix metalloproteinase; membrane-type; osteosarcoma; MT1-MMP; MATRIX-METALLOPROTEINASE; 2; BETA-CATENIN; C-JUN; FUNCTIONAL-CHARACTERIZATION; POOR-PROGNOSIS; CELL INVASION; COLLAGEN I; CANCER; EXPRESSION; ACTIVATION;

D O I：

10.20517/2394-4722.2021.174

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The dysregulation of Membrane - type 1 matrix metalloproteinase (MT1- MMP) has been extensively studied in numerous cancer types, and plays key roles in angiogenesis, cancer progression, and metastasis. MT1-MMP is a predictor of poor prognosis in osteosarcoma (OS), yet the molecular mechanisms of disease progression are unclear. This review provides a summary of the literature relating to the gene and protein expression of MT1-MMP (MMP-14) in OS clinical samples, evaluates the expression in cell lines and experimental models, and analyses its potential role in the progression and metastasis of OS. In addition, the therapeutic potential of MT1-MMP as a drug target has been assessed. Due to the biological complexity of MMPs, inhibition has proven to be challenging. However, exploiting the expression and proteolytic capacity of MT1-MMP could open new avenues in the search for novel, safer and selective drugs for use in OS.

引用

页数：15

共 79 条

[1] Matrix Metalloproteinases: A challenging paradigm of cancer management [J].

Alaseem, Ali ;

Alhazzani, Khalid ;

Dondapati, Priya ;

Alobid, Saad ;

Bishayee, Anupam ;

Rathinavelu, Appu .

SEMINARS IN CANCER BIOLOGY, 2019, 56 :100-115

[2] Pigment epithelium-derived factor upregulates collagen I and downregulates matrix metalloproteinase 2 in osteosarcoma cells, and colocalises to collagen I and heat shock protein 47 in fetal and adult bone [J].

Alcantara, Marice B. ;

Nemazannikova, Natalie ;

Elahy, Mina ;

Dass, Crispin R. .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 2014, 66 (11) :1586-1592

[3]

[Anonymous], BIOL OSTEOSARCOMA BO

[4]

[Anonymous], BT1718 PATIENTS ADV

[5] Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases [J].

Atkinson, Jennifer M. ;

Falconer, Robert A. ;

Edwards, Dylan R. ;

Pennington, Caroline J. ;

Siller, Catherine S. ;

Shnyder, Steven D. ;

Bibby, Michael C. ;

Patterson, Laurence H. ;

Loadman, Paul M. ;

Gill, Jason H. .

CANCER RESEARCH, 2010, 70 (17) :6902-6912

[6]

Beech T., PATIENT PARENT OSTEO

[7] The mechanism of action of BT1718, a novel small-molecule drug conjugate for the treatment of solid tumors expressing MT1-MMP [J].

Bennett, Gavin ;

Rigby, Mike ;

Lutz, Bob ;

Park, Peter ;

Keen, Nicholas .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)

[8] Membrane-Type 1 Matrix Metalloproteinase (MT1-MMP): A predictive biomarker of chemotherapy response in osteosarcoma [J].

Biswas, Swethajit ;

Rankin, Kenneth ;

Long, Anna ;

Nisar, Sohail ;

Gerrand, Craig ;

Dildey, Petra ;

Lunec, John .

CANCER RESEARCH, 2012, 72

[9] Matrix metalloproteinases participate in osteosarcoma invasion [J].

Bjornland, K ;

Flatmark, K ;

Pettersen, S ;

Aaasen, AO ;

Fodstad, O ;

Maelandsmo, GM .

JOURNAL OF SURGICAL RESEARCH, 2005, 127 (02) :151-156

[10]

Bjornland K, 1999, CANCER RES, V59, P4702

← 1 2 3 4 5 6 7 8 →